<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHOTREXATE- methotrexate sodiumÂ injection, powder, lyophilized, for solutionÂ </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Methotrexate for Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e26b569a-c9fc-4f9b-9dc7-b20c983c0f6d"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only </p>
</div>
<div class="Warning">
<a name="b8c166d7-b8ea-4a17-8012-c26047d619cf"></a><a name="section-2"></a><p></p>
<h1>BOXED WARNINGS</h1>
<p class="First">METHOTREXATE SHOULD BE USED ONLY BY PHYSICIANS WHOSE KNOWLEDGE AND EXPERIENCE INCLUDE THE USE OF ANTIMETABOLITE THERAPY.</p>
<p>BECAUSE OF THE POSSIBILITY OF SERIOUS TOXIC REACTIONS (WHICH CAN BE FATAL):</p>
<p>METHOTREXATE SHOULD BE USED ONLY IN LIFE-THREATENING NEOPLASTIC DISEASES, OR IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">PSORIASIS</span> OR <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">RHEUMATOID ARTHRITIS</span> WITH SEVERE, RECALCITRANT, DISABLING DISEASE WHICH IS NOT ADEQUATELY RESPONSIVE TO OTHER FORMS OF THERAPY.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> HAVE BEEN REPORTED WITH THE USE OF METHOTREXATE IN THE TREATMENT OF MALIGNANCY, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">PSORIASIS</span>, AND <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">RHEUMATOID ARTHRITIS</span>.</p>
<p>PATIENTS SHOULD BE CLOSELY MONITORED FOR BONE MARROW, LIVER, LUNG AND KIDNEY TOXICITIES (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>).</p>
<p>PATIENTS SHOULD BE INFORMED BY THEIR PHYSICIAN OF THE RISKS INVOLVED AND BE UNDER A PHYSICIANâ€™S CARE THROUGHOUT THERAPY.</p>
<p>THE USE OF METHOTREXATE HIGH-DOSE REGIMENS RECOMMENDED FOR <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">OSTEOSARCOMA</span> REQUIRES METICULOUS CARE (see <span class="Bold"><span class="Emphasis"><a href="#e98248a4-9a01-4416-bf52-731d8dbed0e5">DOSAGE AND ADMINISTRATION</a></span></span>). Â HIGH-DOSE REGIMENS FOR OTHER NEOPLASTIC DISEASES ARE INVESTIGATIONAL AND A THERAPEUTIC ADVANTAGE HAS NOT BEEN ESTABLISHED.Â Â Â Â Â Â Â Â Â Â Â  </p>
<p>METHOTREXATE FORMULATIONS AND DILUENTS CONTAINING PRESERVATIVES MUST NOT BE USED FOR INTRATHECAL OR HIGH-DOSE METHOTREXATE THERAPY.Â Â 
</p>
<ol>
<li>Methotrexate has been reported to cause <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and/or congenital anomalies. Â Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks. Â Pregnant women with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> should not receive methotrexate (see <span class="Bold"><span class="Emphasis"><a href="#a15d5648-439e-4a6d-b23d-1c02c0329aff">CONTRAINDICATIONS</a></span></span>).</li>
<li>Methotrexate elimination is reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, or <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span>. Â Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. </li>
<li>Unexpectedly severe (sometimes fatal) bone marrow suppression, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span> have been reported with concomitant administration of methotrexate (usually in high dosage) along with some non-steroidal anti-inflammatory drugs (NSAIDs) (see <a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#b8a0ebd0-e0d5-4e2f-8a36-05e2b7e3cd03">Drug Interactions</a></span></span></span>).</li>
<li>Methotrexate causes hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and cirrhosis, but generally only after prolonged use. Â Acutely, liver enzyme elevations are frequently seen. Â These are usually transient and asymptomatic, and also do not appear predictive of subsequent <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.Â  Liver biopsy after sustained use often shows histologic changes, and <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> in the <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> population.Â  For this reason, periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment.Â  Persistent abnormalities in liver function tests may precede appearance of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or cirrhosis in the <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> population (see <a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Organ System Toxicity</a></span></span></span>, <span class="Italics"><span class="Emphasis"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Hepatic</a></span></span>).</li>
<li>Methotrexate-induced <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, including acute or chronic <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. Â It is not always fully reversible and fatalities have been reported.Â  Pulmonary symptoms (especially a dry, nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) may require interruption of treatment and careful investigation.</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span> require interruption of therapy; otherwise, hemorrhagic <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> may occur.</li>
<li><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Malignant lymphomas</span>, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment.Â  Discontinue methotrexate first and, if the <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> does not regress, appropriate treatment should be instituted.</li>
<li>Like other cytotoxic drugs, methotrexate may induce â€œtumor lysis syndromeâ€? in patients with rapidly growing tumors.Â  Appropriate supportive and pharmacologic measures may prevent or alleviate this complication.</li>
<li>Severe, occasionally fatal, <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported following single or multiple doses of methotrexate. Â Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Â Recovery has been reported with discontinuation of therapy (see <a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Organ System Toxicity</a></span></span></span>, <span class="Italics"><span class="Emphasis"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Skin</a></span></span>).Â  </li>
<li>Potentially fatal <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, especially <span class="Italics"><span class="Emphasis">Pneumocystis carinii </span></span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, may occur with methotrexate therapy.</li>
<li>Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="e83e5d25-1540-422f-be3f-37b99038ca81"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Methotrexate (formerly Amethopterin) is an antimetabolite used in the treatment of certain neoplastic diseases, severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, and adult <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
<p>Chemically, methotrexate is <span class="Italics"><span class="Emphasis">N</span></span>-[4-[[(2,4-diamino-6-pteridinyl)methyl]-methylamino]benzoyl]-L-glutamic acid. </p>
<p>The structural formula is: </p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&amp;name=methotrexate-for-injection-usp-figure-1-meth-struct.jpg"></p>
<p>C<span class="Sub">20</span>H<span class="Sub">22</span>N<span class="Sub">8</span>O<span class="Sub">5</span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  M.W. 454.45 </p>
<p>Methotrexate for Injection, is sterile and non-pyrogenic and may be given by the intramuscular, intravenous, intra-arterial or intrathecal route (see <span class="Bold"><span class="Emphasis"><a href="#e98248a4-9a01-4416-bf52-731d8dbed0e5">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p><span class="Italics"><span class="Emphasis">Methotrexate for Injection, USP, Lyophilized, Preservative Free, </span></span>for single use only, is available in 1 gram vials.</p>
<p>Each vial of lyophilized powder contains methotrexate sodium equivalent to 1 g methotrexate.Â  Contains no preservative.Â  Sodium hydroxide and/or hydrochloric acid may be added to adjust the pH during manufacture to 8.5 to 8.7.Â  The 1 g vial contains approximately 7 mEq sodium.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a56aeed2-38b9-4106-9fc1-0082f4a15000"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Methotrexate inhibits dihydrofolic acid reductase.Â  Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate.Â  Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication.Â  Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate.Â  When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues.</p>
<p>The mechanism of action in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> is unknown; it may affect immune function.Â  Two reports describe <span class="Italics"><span class="Emphasis">in vitro </span></span>methotrexate inhibition of DNA precursor uptake by stimulated mononuclear cells, and another describes in animal <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> partial correction by methotrexate of spleen cell hyporesponsiveness and suppressed IL 2 production.Â  Other laboratories, however, have been unable to demonstrate similar effects.Â  Clarification of methotrexateâ€™s effect on immune activity and its relation to rheumatoid immunopathogenesis await further studies.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, effects of methotrexate on articular <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> can be seen as early as 3 to 6 weeks.Â  Although methotrexate clearly ameliorates symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>), there is no evidence that it induces remission of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> nor has a beneficial effect been demonstrated on bone erosions and other radiologic changes which result in impaired joint use, functional <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>, and <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>.</p>
<p>Most studies of methotrexate in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> are relatively short-term (3 to 6 months).Â  Limited data from long-term studies indicate that an initial clinical improvement is maintained for at least two years with continued therapy.</p>
<p>In <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, the rate of production of epithelial cells in the skin is greatly increased over normal skin.Â  This differential in proliferation rates is the basis for the use of methotrexate to control the psoriatic process.</p>
<p>Methotrexate in high doses, followed by leucovorin rescue, is used as a part of the treatment of patients with non-metastatic <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>.Â  The original rationale for high-dose methotrexate therapy was based on the concept of selective rescue of normal tissues by leucovorin.Â  More recent evidence suggests that high-dose methotrexate may also overcome methotrexate resistance caused by impaired active transport, decreased affinity of dihydrofolic acid reductase for methotrexate, increased levels of dihydrofolic acid reductase resulting from gene amplification, or decreased polyglutamation of methotrexate.Â  The actual mechanism of action is unknown.</p>
<p>In a 6-month double-blind, placebo-controlled trial of 127 pediatric patients with <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (JRA) (mean age, 10.1 years; age range, 2.5 to 18 years; mean duration of disease, 5.1 years) on background non-steroidal anti-inflammatory drugs (NSAIDs) and/or prednisone, methotrexate given weekly at an oral dose of 10 mg/m<span class="Sup">2</span> provided significant clinical improvement compared to placebo as measured by either the physicianâ€™s global assessment, or by a patient composite (25% reduction in the articular-severity score plus improvement in parent and physician global assessments of disease activity).Â  Over two-thirds of the patients in this trial had polyarticular-course JRA, and the numerically greatest response was seen in this subgroup treated with 10 mg/m<span class="Sup">2</span>/wk methotrexate.Â  The overwhelming majority of the remaining patients had systemic-course JRA.Â  All patients were unresponsive to NSAIDs; approximately one-third were using low-dose corticosteroids.Â  Weekly methotrexate at a dose of 5 mg/m<span class="Sup">2</span> was not significantly more effective than placebo in this trial.</p>
<p>Two Pediatric Oncology Group studies (one randomized and one non-randomized) demonstrated a significant improvement in relapse-free survival in patients with non-metastatic <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>, when high-dose methotrexate with leucovorin rescue was used in combination with other chemotherapeutic agents following surgical resection of the primary tumor.Â  These studies were not designed to demonstrate the specific contribution of high-dose methotrexate/leucovorin rescue therapy to the efficacy of the combination.Â  However, a contribution can be inferred from the reports of objective responses to this therapy in patients with metastatic <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>, and from reports of extensive <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">tumor necrosis</span> following preoperative administration of this therapy to patients with non-metastatic <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="e85721a1-6cd9-474e-8123-cc19ee38c14d"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Absorption</span></span></p>
<p>In adults, oral absorption appears to be dose dependent.Â  Peak serum levels are reached within one to two hours.Â  At doses of 30 mg/m<span class="Sup">2</span> or less, methotrexate is generally well absorbed with a mean bioavailability of about 60%.Â  The absorption of doses greater than 80 mg/m<span class="Sup">2</span> is significantly less, possibly due to a saturation effect.</p>
<p>In leukemic pediatric patients, oral absorption of methotrexate also appears to be dose dependent and has been reported to vary widely (23% to 95%).Â  A twenty fold difference between highest and lowest peak levels (C<span class="Sub">max</span>: 0.11 to 2.3 micromolar after a 20 mg/m<span class="Sup">2</span> dose) has been reported.Â  Significant interindividual variability has also been noted in time to peak concentration (T<span class="Sub">max</span>: 0.67 to 4 hrs after a 15 mg/m<span class="Sup">2</span> dose) and fraction of dose absorbed.Â  The absorption of doses greater than 40 mg/m<span class="Sup">2</span> has been reported to be significantly less than that of lower doses.Â  Food has been shown to delay absorption and reduce peak concentration.Â  Methotrexate is generally completely absorbed from parenteral routes of injection.Â  After intramuscular injection, peak serum concentrations occur in 30 to 60 minutes.Â  As in leukemic pediatric patients, a wide interindividual variability in the plasma concentrations of methotrexate has been reported in pediatric patients with JRA.Â  Following oral administration of methotrexate in doses of 6.4 to 11.2 mg/m<span class="Sup">2</span>/week in pediatric patients with JRA, mean serum concentrations were 0.59 micromolar (range, 0.03 to 1.4) at 1 hour, 0.44 micromolar (range, 0.01 to 1) at 2 hours, and 0.29 micromolar (range, 0.06 to 0.58) at 3 hours.Â  In pediatric patients receiving methotrexate for <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span> (6.3 to 30 mg/m<span class="Sup">2</span>), or for JRA (3.75 to 26.2 mg/m<span class="Sup">2</span>), the terminal half-life has been reported to range from 0.7 to 5.8 hours or 0.9 to 2.3 hours, respectively. </p>
<p><span class="Italics"><span class="Emphasis">Distribution</span></span></p>
<p>After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40 to 80% of body weight).Â  Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process.Â  At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate in serum is approximately 50% protein bound.Â  Laboratory studies demonstrate that it may be displaced from plasma albumin by various compounds including sulfonamides, salicylates, tetracyclines, chloramphenicol, and phenytoin.</p>
<p>Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given orally or parenterally.Â  High CSF concentrations of the drug may be attained by intrathecal administration.</p>
<p>In dogs, synovial fluid concentrations after oral dosing were higher in inflamed than uninflamed joints.Â  Although salicylates did not interfere with this penetration, prior prednisone treatment reduced penetration into inflamed joints to the level of normal joints.</p>
<p><span class="Italics"><span class="Emphasis">Metabolism</span></span></p>
<p>After absorption, methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthetase.Â  Small amounts of methotrexate polyglutamates may remain in tissues for extended periods. The retention and prolonged drug action of these active metabolites vary among different cells, tissues and tumors.Â  A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed.Â  Accumulation of this metabolite may become significant at the high doses used in <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteogenic sarcoma</span>.Â  The aqueous solubility of 7-hydroxymethotrexate is 3 to 5 fold lower than the parent compound. Methotrexate is partially metabolized by intestinal flora after oral administration.</p>
<p>Â </p>
<span class="Italics"><span class="Emphasis">Half-Life</span></span><p>The terminal half-life reported for methotrexate is approximately three to ten hours for patients receiving treatment for <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> or low-dose antineoplastic therapy (less than 30 mg/m<span class="Sup">2</span>).Â  For patients receiving high doses of methotrexate, the terminal half-life is eight to 15 hours. </p>
<p><span class="Italics"><span class="Emphasis">Excretion</span></span></p>
<p>Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration.Â  With IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours.Â  There is limited biliary excretion amounting to 10% or less of the administered dose. Enterohepatic recirculation of methotrexate has been proposed.</p>
<p>Renal excretion occurs by glomerular filtration and active tubular secretion.Â  Non-linear elimination due to saturation of renal tubular reabsorption has been observed in psoriatic patients at doses between 7.5 and 30 mg.Â  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span>, as well as concurrent use of drugs such as weak organic acids that also undergo tubular secretion, can markedly increase methotrexate serum levels.Â  Excellent correlation has been reported between methotrexate clearance and endogenous creatinine clearance.</p>
<p>Methotrexate clearance rates vary widely and are generally decreased at higher doses.Â  Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity.Â  It has been postulated that the toxicity of methotrexate for normal tissues is more dependent upon the duration of exposure to the drug rather than the peak level achieved.Â  When a patient has delayed drug elimination due to compromised renal function, a third space <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span>, or other causes, methotrexate serum concentrations may remain elevated for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>.</p>
<p>The potential for toxicity from high-dose regimens or delayed excretion is reduced by the administration of leucovorin calcium during the final phase of methotrexate plasma elimination.Â  Pharmacokinetic monitoring of methotrexate serum concentrations may help identify those patients at high risk for methotrexate toxicity and aid in proper adjustment of leucovorin dosing.Â  Guidelines for monitoring serum methotrexate levels, and for adjustment of leucovorin dosing to reduce the risk of methotrexate toxicity, are provided below in <span class="Bold"><span class="Emphasis"><a href="#e98248a4-9a01-4416-bf52-731d8dbed0e5">DOSAGE AND ADMINISTRATION</a></span></span>.</p>
<p>Methotrexate has been detected in human breast milk.Â  The highest breast milk to plasma concentration ratio reached was 0.08:1.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ea0a8011-926c-4730-9277-2f31f09e84d0"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="d16f2053-fd8d-4b84-8b68-9f671c4fd509"></a><a name="section-4.1"></a><p></p>
<h2>Neoplastic Diseases</h2>
<p class="First">Methotrexate is indicated in the treatment of gestational <span class="product-label-link" type="condition" conceptid="4092517" conceptname="Choriocarcinoma">choriocarcinoma</span>, chorioadenoma destruens and hydatidiform mole. </p>
<p>In <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span>, methotrexate is indicated in the prophylaxis of meningeal <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and is used in maintenance therapy in combination with other chemotherapeutic agents.Â  Methotrexate is also indicated in the treatment of meningeal <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.</p>
<p>Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span> (cutaneous T cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), and lung cancer, particularly squamous cell and small cell types.Â  Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkinâ€™s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
<p>Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span> who have undergone surgical resection or amputation for the primary tumor.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="fa7ec297-e628-4e7e-81bf-585b5f09d228"></a><a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></h2>
<p class="First">Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> that is not adequately responsive to other forms of therapy, <span class="Italics"><span class="Emphasis">but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation.</span></span>Â  It is important to ensure that a <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> â€œflareâ€? is not due to an undiagnosed concomitant disease affecting immune responses.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a811b138-bb06-42e9-9866-8f4dd941c98a"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> including Polyarticular-Course <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">Juvenile Rheumatoid Arthritis</span></h2>
<p class="First">Methotrexate is indicated in the management of selected adults with severe, active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (ACR criteria), or children with active polyarticular-course <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span>, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).</p>
<p>Aspirin, (NSAIDs), and/or low-dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored (see <a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#b8a0ebd0-e0d5-4e2f-8a36-05e2b7e3cd03">Drug Interactions</a></span></span></span>).Â  Steroids may be reduced gradually in patients who respond to methotrexate.Â  Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects.Â  Rest and physiotherapy as indicated should be continued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a15d5648-439e-4a6d-b23d-1c02c0329aff"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Methotrexate can cause <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> or teratogenic effects when administered to a pregnant woman.Â  Methotrexate is contraindicated in pregnant women with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus.Â  Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counseled on the serious risk to the fetus (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>) should they become pregnant while undergoing treatment.Â  Pregnancy should be avoided if either partner is receiving methotrexate; during and for a minimum of three months after therapy for male patients, and during and for at least one ovulatory cycle after therapy for female patients (see <span class="Bold"><span class="Emphasis"><a href="#b8c166d7-b8ea-4a17-8012-c26047d619cf">BOXED WARNINGS</a></span></span>).</p>
<p>Because of the potential for serious adverse reactions from methotrexate in breast fed infants, it is contraindicated in nursing mothers.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> with <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span> or other <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> should not receive methotrexate. </p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who have overt or laboratory evidence of <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> syndromes should not receive methotrexate.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who have pre-existing <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, such as bone <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or significant <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, should not receive methotrexate.</p>
<p>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to methotrexate should not receive the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ca49feb5-d361-4e51-bbc6-d8a16fbb8592"></a><a name="section-6"></a><p></p>
<h1>WARNINGS<br>
</h1>
<p class="First"><span class="Bold"><span class="Emphasis">SEE <a href="#b8c166d7-b8ea-4a17-8012-c26047d619cf">BOXED WARNINGS</a>. </span></span></p>
<p>Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitor (PPI) therapy.Â  Case reports and published population pharmacokinetic studies suggest that concomitant use of PPIs, such as omeprazole, esomeprazole and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities.Â  In two of these cases, delayed methotrexate elimination was observed when high-dose methotrexate was co-administered with PPIs, but was not observed when methotrexate was co-administered with ranitidine.Â  However, no formal drug interaction studies of methotrexate with ranitidine have been conducted.</p>
<p>Methotrexate formulations and diluents containing preservatives must not be used for intrathecal or high-dose methotrexate therapy. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a38ec796-9705-4763-8802-3a88cd2e26c8"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="f7343bfa-2053-45cb-bf14-42b36055ac3b"></a><a name="section-7.1"></a><p></p>
<h2>General<br>
</h2>
<p class="First">Methotrexate has the potential for serious toxicity (see <span class="Bold"><span class="Emphasis"><a href="#b8c166d7-b8ea-4a17-8012-c26047d619cf">BOXED </a><a href="#b8c166d7-b8ea-4a17-8012-c26047d619cf">WARNINGS</a></span></span>).Â  Toxic effects may be related in frequency and severity to dose or frequency of administration but have been seen at all doses.Â  Because they can occur at any time during therapy, it is necessary to follow patients on methotrexate closely.Â  Most adverse reactions are reversible if detected early.Â  When such reactions do occur, the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken.Â  If necessary, this could include the use of leucovorin calcium and/or acute, intermittent hemodialysis with a high-flux dialyzer (see <span class="Bold"><span class="Emphasis"><a href="#b596854e-3504-422f-9d2c-42cf125c44fb">OVERDOSAGE</a></span></span>).Â  If methotrexate therapy is reinstituted, it should be carried out with caution, with adequate consideration of further need for the drug and with increased alertness as to possible recurrence of toxicity.</p>
<p>The clinical pharmacology of methotrexate has not been well studied in older individuals.Â  Due to diminished hepatic and renal function as well as decreased folate stores in this population, relatively low doses should be considered, and these patients should be closely monitored for early signs of toxicity. </p>
<p>Some of the effects mentioned under <span class="Bold"><span class="Emphasis"><a href="#a9b7e966-af5e-44a9-bb63-a00d00547551">ADVERSE REACTIONS</a></span></span>, such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, may affect the ability to drive or operate machinery.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c97c9e33-380a-4144-8b10-ac48208d54f5"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients<br>
</h2>
<p class="First">Patients should be informed of the early signs and symptoms of toxicity, of the need to see their physician promptly if they occur, and the need for close follow-up, including periodic laboratory tests to monitor toxicity.</p>
<p>Both the physician and pharmacist should emphasize to the patient that the recommended dose is taken weekly in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, and that mistaken daily use of the recommended dose has led to fatal toxicity.Â  Prescriptions should not be written or refilled on a PRN basis. </p>
<p>Patients should be informed of the potential benefit and risk in the use of methotrexate.Â  The risk of effects on reproduction should be discussed with both male and female patients taking methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f27f35dd-8509-441d-b345-c1ca3d4f7d82"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests<br>
</h2>
<p class="First">Patients undergoing methotrexate therapy should be closely monitored so that toxic effects are detected promptly.Â  Baseline assessment should include a complete blood count with differential and platelet counts, hepatic enzymes, renal function tests, and a chest X-ray.Â  During therapy of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, monitoring of these parameters is recommended: hematology at least monthly, renal function and liver function every 1 to 2 months.Â  More frequent monitoring is usually indicated during antineoplastic therapy.Â  <span class="Italics"><span class="Emphasis">During initial or changing doses,</span></span> or during periods of increased risk of elevated methotrexate blood levels (e.g., <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>), more frequent monitoring may also be indicated.</p>
<p>Transient liver function test abnormalities are observed frequently after methotrexate administration and are usually not cause for modification of methotrexate therapy.Â  Persistent liver function test abnormalities, and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of serum albumin may be indicators of serious liver toxicity and require evaluation (see <a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Organ System Toxicity</a></span></span></span><span class="Bold"><span class="Emphasis">, </span></span><span class="Italics"><span class="Emphasis"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Hepatic</a></span></span>). </p>
<p>A relationship between <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> and <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or cirrhosis of the liver has not been established for patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.Â  Persistent abnormalities in liver function tests may precede appearance of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or cirrhosis in the <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> population.</p>
<p>Pulmonary function tests may be useful if methotrexate-induced <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> is suspected, especially if baseline measurements are available.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b8a0ebd0-e0d5-4e2f-8a36-05e2b7e3cd03"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Non-steroidal anti-inflammatory drugs should not be administered prior to or concomitantly with the high doses of methotrexate, such as used in the treatment of <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>.Â  Concomitant administration of some NSAIDs with high-dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> from severe hematologic and <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>.</p>
<p>Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate.Â  These drugs have been reported to reduce the tubular secretion of methotrexate in an animal model and may enhance its toxicity.</p>
<p>Despite the potential interactions, studies of methotrexate in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> have usually included concurrent use of constant dosage regimens of NSAIDs, without apparent problems.Â  It should be appreciated, however, that the doses used in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (7.5 to 15 mg/week) are somewhat lower than those used in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> and that larger doses could lead to unexpected toxicity.</p>
<p>Methotrexate is partially bound to serum albumin, and toxicity may be increased because of displacement by certain drugs, such as salicylates, phenylbutazone, phenytoin, and sulfonamides.Â  Renal tubular transport is also diminished by probenecid; use of methotrexate with this drug should be carefully monitored.</p>
<p>In the treatment of patients with <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>, caution must be exercised if high-dose methotrexate is administered in combination with a potentially nephrotoxic chemotherapeutic agent (e.g., cisplatin).</p>
<p>Methotrexate increases the plasma levels of mercaptopurine.Â  The combination of methotrexate and mercaptopurine may therefore require dose adjustment.</p>
<p>Oral antibiotics such as tetracycline, chloramphenicol, and non-absorbable broad spectrum antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria.</p>
<p>Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span> have been observed with high- and low-dose methotrexate.Â  Use of methotrexate with penicillins should be carefully monitored.</p>
<p>The potential for increased hepatotoxicity when methotrexate is administered with other hepatotoxic agents has not been evaluated.Â  However, hepatotoxicity has been reported in such cases.Â  Therefore, patients receiving concomitant therapy with methotrexate and other potential hepatotoxins (e.g., azathioprine, retinoids, sulfasalazine) should be closely monitored for possible increased risk of hepatotoxicity.</p>
<p>Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when used concurrently with methotrexate.</p>
<p>Vitamin preparations containing folic acid or its derivatives may decrease responses to systemically administered methotrexate.Â  Preliminary animal and human studies have shown that small quantities of intravenously administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.Â  However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.</p>
<p><span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">Folate deficiency</span> states may increase methotrexate toxicity.Â  Trimethoprim/sulfamethoxazole has been reported rarely to increase bone marrow suppression in patients receiving methotrexate, probably by decreased tubular secretion and/or additive antifolate effect.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e2f69f01-c36e-40a1-acb3-58e675ae0077"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility<br>
</h2>
<p class="First">No controlled human data exist regarding the risk of neoplasia with methotrexate.Â  Methotrexate has been evaluated in a number of animal studies for carcinogenic potential with inconclusive results.Â  Although there is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells, the clinical significance remains uncertain.Â  Non-Hodgkinâ€™s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other tumors have been reported in patients receiving low-dose oral methotrexate.Â  However, there have been instances of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphoma</span> arising during treatment with low-dose oral methotrexate, which have regressed completely following withdrawal of methotrexate, without requiring active anti-<span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> treatment.Â  Benefits should be weighed against the potential risks before using methotrexate alone or in combination with other drugs, especially in pediatric patients or young adults.Â  Methotrexate causes embryotoxicity, abortion, and fetal defects in humans.Â  It has also been reported to cause impairment of fertility, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> and menstrual dysfunction in humans, during and for a short period after cessation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="eee2406a-c96a-4172-9f4e-b80c13112084"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>: Methotrexate is in Pregnancy Category X (see <span class="Bold"><span class="Emphasis"><a href="#a15d5648-439e-4a6d-b23d-1c02c0329aff">CONTRAINDICATIONS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ef05b56f-d1be-41d1-9eda-01f1f2834707"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">See <span class="Bold"><span class="Emphasis"><a href="#a15d5648-439e-4a6d-b23d-1c02c0329aff">CONTRAINDICATIONS</a></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fb2ecac6-2b58-48f0-b1e7-a499bc582f23"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have been established only in cancer chemotherapy and in polyarticular-course <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span>.</p>
<p>Published clinical studies evaluating the use of methotrexate in children and adolescents (i.e., patients 2 to 16 years of age) with JRA demonstrated safety comparable to that observed in adults with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (see<span class="Bold"><span class="Emphasis"><a href="#a56aeed2-38b9-4106-9fc1-0082f4a15000"> CLINICAL PHARMACOLOGY</a></span></span>, <span class="Bold"><span class="Emphasis"><a href="#a9b7e966-af5e-44a9-bb63-a00d00547551">ADVERSE REACTIONS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#e98248a4-9a01-4416-bf52-731d8dbed0e5">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>Methotrexate injectable formulations containing the preservative benzyl alcohol are not recommended for use in neonates.Â  There have been reports of fatal â€˜<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndromeâ€™ in neonates (children less than one month of age) following the administrations of intravenous solutions containing the preservative benzyl alcohol.Â  Symptoms include a striking onset of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respiration, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, frequently manifested as generalized or <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">focal seizures</span>, has been reported with unexpectedly increased frequency among pediatric patients with <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> who were treated with intermediate-dose intravenous methotrexate (1 gm/m<span class="Sup">2</span>) (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e6d1e864-6db4-4026-9518-aa977aba5aa7">Organ System Toxicity</a></span></span></span>, <span class="Italics"><span class="Emphasis">Neurologic</span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d32aa4a6-de12-4a0d-b61b-4f5245e1ed4a"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of methotrexate did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.Â  In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic and renal function, decreased folate stores, concomitant disease or other drug therapy (i.e., that interfere with renal function, methotrexate or folate metabolism) in this population (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>,<span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#b8a0ebd0-e0d5-4e2f-8a36-05e2b7e3cd03"> Drug Interactions</a></span></span></span>).Â  Since decline in renal function may be associated with increases in adverse events and serum creatinine measurements may over estimate renal function in the elderly, more accurate methods (i.e., creatinine clearance) should be considered.Â  Serum methotrexate levels may also be helpful.Â  Elderly patients should be closely monitored for early signs of hepatic, bone marrow and renal toxicity.Â  In chronic use situations, certain toxicities may be reduced by folate supplementation.Â  Post-marketing experience suggests that the occurrence of bone marrow suppression, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> may increase with age (see <span class="Bold"><span class="Emphasis"><a href="#b8c166d7-b8ea-4a17-8012-c26047d619cf">BOXED </a><a href="#b8c166d7-b8ea-4a17-8012-c26047d619cf">WARNINGS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#a9b7e966-af5e-44a9-bb63-a00d00547551">ADVERSE REACTIONS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e6d1e864-6db4-4026-9518-aa977aba5aa7"></a><a name="section-7.10"></a><p></p>
<h2>Organ System Toxicity</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Gastrointestinal</span></span></p>
<p>If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> occur, which may result in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, methotrexate should be discontinued until recovery occurs.Â  Methotrexate should be used with extreme caution in the presence of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. </p>
<p><span class="Italics"><span class="Emphasis">Hematologic</span></span></p>
<p>Methotrexate can suppress hematopoiesis and cause <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and/or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.Â  In patients with malignancy and pre-existing hematopoietic impairment, the drug should be used with caution, if at all.Â  In controlled clinical trials in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (n=128), <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (WBC &lt;3,000/mm<span class="Sup">3</span>) was seen in 2 patients, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelets &lt;100,000/mm<span class="Sup">3</span>) in 6 patients, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> in 2 patients.</p>
<p>In <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, methotrexate should be stopped immediately if there is a significant drop in blood counts.Â  In the treatment of neoplastic diseases, methotrexate should be continued only if the potential benefit warrants the risk of severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>.Â  Patients with profound <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> should be evaluated immediately and usually require parenteral broad-spectrum antibiotic therapy.</p>
<p><span class="Italics"><span class="Emphasis">Hepatic</span></span></p>
<p>Methotrexate has the potential for acute (elevated transaminases) and chronic (<span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and cirrhosis) hepatotoxicity.Â  Chronic toxicity is potentially fatal; it generally has occurred after prolonged use (generally two years or more) and after a total dose of at least 1.5 grams.Â  In studies in psoriatic patients, hepatotoxicity appeared to be a function of total cumulative dose and appeared to be enhanced by <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and advanced age.Â  An accurate incidence rate has not been determined; the rate of progression and reversibility of lesions is not known.Â  Special caution is indicated in the presence of pre-existing <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> or impaired hepatic function.</p>
<p>In <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, liver function tests, including serum albumin, should be performed periodically prior to dosing but are often normal in the face of developing <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or cirrhosis.Â  These lesions may be detectable only by biopsy.Â  The usual recommendation is to obtain a liver biopsy at 1) pretherapy or shortly after initiation of therapy (2 to 4 months), 2) a total cumulative dose of 1.5 grams, and 3) after each additional 1 to 1.5 grams.Â  Moderate <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or any cirrhosis normally leads to discontinuation of the drug; mild <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> normally suggests a repeat biopsy in 6 months.Â  Milder histologic findings such as fatty change and low-grade portal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> are relatively common pretherapy.Â  Although these mild changes are usually not a reason to avoid or discontinue methotrexate therapy, the drug should be used with caution.</p>
<p>In <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, age at first use of methotrexate and duration of therapy have been reported as risk factors for hepatotoxicity; other risk factors, similar to those observed in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, may be present in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> but have not been confirmed to date.Â  Persistent abnormalities in liver function tests may precede appearance of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> or cirrhosis in this population.Â  There is a combined reported experience in 217 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients with liver biopsies both before and during treatment (after a cumulative dose of at least 1.5 g) and in 714 patients with a biopsy only during treatment.Â  There are 64 (7%) cases of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and 1 (0.1%) case of cirrhosis.Â  Of the 64 cases of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, 60 were deemed mild.Â  The reticulin stain is more sensitive for early <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and its use may increase these figures.Â  It is unknown whether even longer use will increase these risks.</p>
<p>Liver function tests should be performed at baseline and at 4 to 8 week intervals in patients receiving methotrexate for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.Â  Pretreatment liver biopsy should be performed for patients with a history of excessive alcohol consumption, persistently abnormal baseline liver function test values or <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.Â  During therapy, liver biopsy should be performed if there are persistent liver function test abnormalities or there is a decrease in serum albumin below the normal range (in the setting of well controlled <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>).</p>
<p>If the results of a liver biopsy show mild changes (Roenigk grades I, II, IIIa), methotrexate may be continued and the patient monitored as per recommendations listed above.Â  Methotrexate should be discontinued in any patient who displays persistently <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> and refuses liver biopsy or in any patient whose liver biopsy shows moderate to severe changes (Roenigk grade IIIb or IV).</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> or Immunologic States</span></span></p>
<p>Methotrexate should be used with extreme caution in the presence of active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and is usually contraindicated in patients with overt or laboratory evidence of <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> syndromes.Â  Immunization may be ineffective when given during methotrexate therapy.Â  Immunization with live virus vaccines is generally not recommended.Â  There have been reports of disseminated <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> after <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span> immunization in patients receiving methotrexate therapy.Â  <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">Hypogammaglobulinemia</span> has been reported rarely.</p>
<p>Potentially fatal <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, especially <span class="Italics"><span class="Emphasis">Pneumocystis carinii</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, may occur with methotrexate therapy.Â  When a patient presents with pulmonary symptoms, the possibility of <span class="Italics"><span class="Emphasis">Pneumocystis carinii</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> should be considered. </p>
<p><span class="Italics"><span class="Emphasis">Neurologic </span></span></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span> following intravenous administration of methotrexate to patients who have had craniospinal irradiation.Â  Serious <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, frequently manifested as generalized or <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">focal seizures</span>, has been reported with unexpectedly increased frequency among pediatric patients with <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> who were treated with intermediate-dose intravenous methotrexate (1 gm/m<span class="Sup">2</span>).Â  Symptomatic patients were commonly noted to have <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span> and/or microangiopathic calcifications on diagnostic imaging studies.Â  Chronic <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span> has also been reported in patients who received repeated doses of high-dose methotrexate with leucovorin rescue even without cranial irradiation.Â  Discontinuation of methotrexate does not always result in complete recovery.</p>
<p>A transient acute neurologic syndrome has been observed in patients treated with high dose regimens.Â  Manifestations of this <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>-like <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> may include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.Â  The exact cause is unknown.</p>
<p>After the intrathecal use of methotrexate, the central nervous system toxicity which may occur can be classified as follows: acute chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> manifested by such symptoms as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; sub-acute <span class="product-label-link" type="condition" conceptid="135526" conceptname="Spinal cord disease">myelopathy</span> characterized by <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span> associated with involvement with one or more spinal nerve roots; chronic <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span> manifested by <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.Â  This condition can be progressive and even fatal.</p>
<p><span class="Italics"><span class="Emphasis">Pulmonary</span></span></p>
<p>Pulmonary symptoms (especially a dry nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) or a nonspecific <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> occurring during methotrexate therapy may be indicative of a potentially dangerous lesion and require interruption of treatment and careful investigation.Â  Although clinically variable, the typical patient with methotrexate-induced <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> presents with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, and an infiltrate on chest X-ray; <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) needs to be excluded.Â  This lesion can occur at all dosages. </p>
<p><span class="Italics"><span class="Emphasis">Renal</span></span></p>
<p>Methotrexate may cause renal damage that may lead to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.Â  High doses of methotrexate used in the treatment of <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span> may cause renal damage leading to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.Â  <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> is due primarily to the precipitation of methotrexate and 7-hydroxymethotrexate in the renal tubules.Â  Close attention to renal function including adequate hydration, urine alkalinization and measurement of serum methotrexate and creatinine levels are essential for safe administration. </p>
<p><span class="Italics"><span class="Emphasis">Skin</span></span></p>
<p>Severe, occasionally fatal, dermatologic reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, have been reported in children and adults, within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration.Â  Reactions were noted after single or multiple, low, intermediate or high doses of methotrexate in patients with neoplastic and non-neoplastic diseases. </p>
<p><span class="Italics"><span class="Emphasis">Other Precautions</span></span></p>
<p>Methotrexate should be used with extreme caution in the presence of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">debility</span>.</p>
<p>Methotrexate exits slowly from third space compartments (e.g., <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span> or <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>).Â  This results in a prolonged terminal plasma half-life and unexpected toxicity.Â  In patients with significant third space accumulations, it is advisable to evacuate the fluid before treatment and to monitor plasma methotrexate levels.</p>
<p>Lesions of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> may be aggravated by concomitant exposure to ultraviolet radiation.Â  Radiation <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> and sunburn may be â€œrecalledâ€? by the use of methotrexate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a9b7e966-af5e-44a9-bb63-a00d00547551"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">IN GENERAL, THE INCIDENCE AND SEVERITY OF ACUTE SIDE EFFECTS ARE RELATED TO DOSE AND FREQUENCY OF ADMINISTRATION</span></span>.Â <span class="Bold"><span class="Emphasis"> THE MOST SERIOUS REACTIONS ARE DISCUSSED ABOVE UNDER ORGAN SYSTEM TOXICITY IN THE PRECAUTIONS SECTION</span></span>.<span class="Bold"><span class="Emphasis">Â  THAT SECTION SHOULD ALSO BE CONSULTED WHEN LOOKING FOR INFORMATION ABOUT ADVERSE REACTIONS WITH METHOTREXATE</span></span>.</p>
<p>The most frequently reported adverse reactions include <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>.Â  Other frequently reported adverse effects are <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, undue <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>Other adverse reactions that have been reported with methotrexate are listed below by organ system.Â  In the oncology setting, concomitant treatment and the underlying disease make specific attribution of a reaction to methotrexate difficult. </p>
<p><span class="Italics"><span class="Emphasis">Alimentary System:</span></span> <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, gastrointestinal ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. </p>
<p><span class="Italics"><span class="Emphasis">Blood and Lymphatic System Disorders:</span></span> suppressed hematopoiesis, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> and <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> (including reversible).Â  <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">Hypogammaglobulinemia</span> has been reported rarely. </p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (including <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>). </p>
<p><span class="Italics"><span class="Emphasis">Central Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span>, speech impairment including <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span> and <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have also occurred following administration of methotrexate.Â  Following low doses, there have been occasional reports of transient subtle cognitive dysfunction, mood alteration, unusual cranial sensations, <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span>, or <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. </p>
<p><span class="Italics"><span class="Emphasis">Hepatobiliary Disorders:</span></span> hepatotoxicity, acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, chronic <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and cirrhosis, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, decrease in serum albumin, liver enzyme elevations. </p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span></span> There have been case reports of sometimes fatal <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> in patients receiving methotrexate therapy for neoplastic and non-neoplastic diseases.Â  <span class="Italics"><span class="Emphasis">Pneumocystis carinii </span></span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> was the most common <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>.Â  There have also been reports of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">Cytomegalovirus infection</span>, including cytomegaloviral <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, fatal <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4104668" conceptname="Nocardiosis">nocardiosis</span>; <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">cryptococcosis</span>, <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span>, H. simplex</span></span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and disseminated <span class="Italics"><span class="Emphasis">H. simplex</span></span>. </p>
<p><span class="Italics"><span class="Emphasis">Musculoskeletal System:</span></span> <span class="product-label-link" type="condition" conceptid="4050742" conceptname="Stress fracture">stress fracture</span>. </p>
<p><span class="Italics"><span class="Emphasis">Ophthalmic:</span></span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, serious visual changes of unknown etiology. </p>
<p><span class="Italics"><span class="Emphasis">Pulmonary System:</span></span> respiratory <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, alveolitis, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported, and chronic interstitial obstructive pulmonary disease has occasionally occurred. </p>
<p><span class="Italics"><span class="Emphasis">Skin:</span></span> erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, pigmentary changes, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>. </p>
<p><span class="Italics"><span class="Emphasis">Urogenital System:</span></span> severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>; defective oogenesis or spermatogenesis, transient <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>, menstrual dysfunction, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>; <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, abortion, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, fetal defects.</p>
<p>Other rarer reactions related to or attributed to the use of methotrexate such as nodulosis, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>/<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>/<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, including reversible <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span>, soft tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>.Â  <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="b6e89083-c377-4c5a-b790-3f2a532bbb23"></a><a name="section-8.1"></a><p></p>
<h2>Adverse Reactions in Double-Blind <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> Studies</h2>
<p class="First">The approximate incidences of methotrexate-attributed (i.e., placebo rate subtracted) adverse reactions in 12 to 18 week double-blind studies of patients (n=128) with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> treated with low-dose oral (7.5 to 15 mg/week) pulse methotrexate, are listed below.Â  Virtually all of these patients were on concomitant non-steroidal anti-inflammatory drugs and some were also taking low dosages of corticosteroids.Â  Hepatic histology was not examined in these short-term studies (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>).</p>
<p>Incidence greater than 10%: Elevated liver function tests 15%, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> 10%.</p>
<p>Incidence 3% to 10%: <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet count less than 100,000/mm<span class="Sup">3</span>).</p>
<p>Incidence 1% to 3%: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>/<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (WBC less than 3,000/mm<span class="Sup">3</span>), <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Two other controlled trials of patients (n=680) with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> on 7.5 mg to 15 mg/wk oral doses showed an incidence of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> of 1% (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>).</p>
<p>Other less common reactions included decreased hematocrit, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, eye <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="e3dbd958-db28-480c-a02f-77ecffb88b19"></a><a name="section-8.2"></a><p></p>
<h2>Adverse Reactions in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></h2>
<p class="First">There are no recent placebo-controlled trials in patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.Â  There are two literature reports (Roenigk, 1969 and Nyfors, 1978) describing large series (n=204, 248) of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> patients treated with methotrexate.Â  Dosages ranged up to 25 mg per week and treatment was administered for up to four years.Â  With the exception of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, and â€œburning of skin lesionsâ€? (each 3% to 10%), the adverse reaction rates in these reports were very similar to those in the <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> studies.Â  Rarely, painful plaque erosions may appear (Pearce, HP and Wilson, BB: <span class="Italics"><span class="Emphasis">Am Acad Dermatol 35:</span></span> 835-838,1996).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b5021a4d-5bf5-4eee-9a3b-eda0f6f0bb33"></a><a name="section-8.3"></a><p></p>
<h2>Adverse Reactions in JRA Studies</h2>
<p class="First">The approximate incidences of adverse reactions reported in pediatric patients with JRA treated with oral, weekly doses of methotrexate (5 to 20 mg/m<span class="Sup">2</span>/wk or 0.1 to 0.65 mg/kg/wk) were as follows (virtually all patients were receiving concomitant non-steroidal anti-inflammatory drugs, and some also were taking low doses of corticosteroids): elevated liver function tests, 14%; gastrointestinal reactions (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), 11%; <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, 2%; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, 2%; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, 1.2%; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, 0.5%; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, 0.2%; and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, 0.2%.Â  Although there is experience with dosing up to 30 mg/m<span class="Sup">2</span>/wk in JRA, the published data for doses above 20 mg/m<span class="Sup">2</span>/wk are too limited to provide reliable estimates of adverse reaction rates.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="b596854e-3504-422f-9d2c-42cf125c44fb"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Leucovorin is indicated to diminish the toxicity and counteract the effect of inadvertently administered overdosages of methotrexate.Â  Leucovorin administration should begin as promptly as possible.Â  As the time interval between methotrexate administration and leucovorin initiation increases, the effectiveness of leucovorin in counteracting toxicity decreases.Â  Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.</p>
<p>In cases of massive overdosage, hydration and urinary alkalinization may be necessary to prevent the precipitation of methotrexate and/or its metabolites in the renal tubules.Â  Generally speaking, neither hemodialysis nor peritoneal dialysis have been shown to improve methotrexate elimination.Â  However, effective clearance of methotrexate has been reported with acute, intermittent hemodialysis using a high-flux dialyzer (Wall, SM et al:<span class="Italics"><span class="Emphasis"> Am J Kidney Dis </span></span>28(6):846-854,1996).</p>
<p>Accidental intrathecal overdosage may require intensive systemic support, high-dose systemic leucovorin, alkaline <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and rapid CSF drainage and ventriculolumbar perfusion.</p>
<p>In post-marketing experience, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with methotrexate has generally occurred with oral and intrathecal administration, although intravenous and intramuscular <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have also been reported.</p>
<p>Reports of oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> often indicate accidental daily administration instead of weekly (single or divided doses).Â  Symptoms commonly reported following oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include those symptoms and signs reported at pharmacologic doses, particularly hematologic and gastrointestinal reaction.Â  For example, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4260546" conceptname="Ulcerative stomatitis">oral ulceration</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastrointestinal ulceration, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.Â  In some cases, no symptoms were reported.Â  There have been reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.Â  In these cases, events such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> were also reported.</p>
<p>Symptoms of intrathecal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are generally central nervous system (CNS) symptoms, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, and acute <span class="product-label-link" type="condition" conceptid="373764" conceptname="Toxic encephalopathy">toxic encephalopathy</span>.Â  In some cases, no symptoms were reported.Â  There have been reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following intrathecal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.Â  In these cases, cerebellar herniation associated with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>, and acute <span class="product-label-link" type="condition" conceptid="373764" conceptname="Toxic encephalopathy">toxic encephalopathy</span> have also been reported.
</p>
<p>There are published case reports of intravenous and intrathecal carboxypeptidase G2 treatment to hasten clearance of methotrexate in cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e98248a4-9a01-4416-bf52-731d8dbed0e5"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="f7a8126c-9410-4949-9b52-9d7e3aac3c7e"></a><a name="section-10.1"></a><p></p>
<h2>Neoplastic Diseases</h2>
<p class="First">Oral administration in tablet form is often preferred when low doses are being administered since absorption is rapid and effective serum levels are obtained.Â  Methotrexate for Injection, USP may be given by the intramuscular, intravenous, intra-arterial or intrathecal route.Â  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4092517" conceptname="Choriocarcinoma">Choriocarcinoma</span> and Similar Trophoblastic Diseases</span></span></p>
<p>Methotrexate is administered orally or intramuscularly in doses of 15 to 30 mg daily for a five-day course.Â  Such courses are usually repeated for 3 to 5 times as required, with rest periods of one or more weeks interposed between courses, until any manifesting toxic symptoms subside.Â  The effectiveness of therapy is ordinarily evaluated by 24 hour quantitative analysis of urinary chorionic gonadotropin (hCG), which should return to normal or less than 50 IU/24 hr usually after the third or fourth course and usually be followed by a complete resolution of measurable lesions in 4 to 6 weeks.Â  One to two courses of methotrexate after normalization of hCG is usually recommended.Â  Before each course of the drug careful clinical assessment is essential.Â  Cyclic combination therapy of methotrexate with other antitumor drugs has been reported as being useful.</p>
<p>Since hydatidiform mole may precede <span class="product-label-link" type="condition" conceptid="4092517" conceptname="Choriocarcinoma">choriocarcinoma</span>, <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> chemotherapy with methotrexate has been recommended.</p>
<p>Chorioadenoma destruens is considered to be an invasive form of hydatidiform mole.Â  Methotrexate is administered in these disease states in doses similar to those recommended for <span class="product-label-link" type="condition" conceptid="4092517" conceptname="Choriocarcinoma">choriocarcinoma</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute lymphoblastic leukemia</span> in pediatric patients and young adolescents is the most responsive to present day chemotherapy.Â  In young adults and older patients, clinical remission is more difficult to obtain and early relapse is more common.</p>
<p>Methotrexate alone or in combination with steroids was used initially for induction of remission in <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemias</span>.Â  More recently corticosteroid therapy, in combination with other antileukemic drugs or in cyclic combinations with methotrexate included, has appeared to produce rapid and effective remissions.Â  When used for induction, methotrexate in doses of 3.3 mg/m<span class="Sup">2</span> in combination with 60 mg/m<span class="Sup">2</span> of prednisone, given daily, produced remissions in 50% of patients treated, usually within a period of 4 to 6 weeks.Â  Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions.Â  When remission is achieved and supportive care has produced general clinical improvement, maintenance therapy is initiated, as follows: Methotrexate is administered 2 times weekly either by mouth or intramuscularly in total weekly doses of 30 mg/m<span class="Sup">2</span>.Â  It has also been given in doses of 2.5 mg/kg intravenously every 14 days.Â  If and when relapse does occur, reinduction of remission can again usually be obtained by repeating the initial induction regimen.</p>
<p>A variety of combination chemotherapy regimens have been used for both induction and maintenance therapy in <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span>.Â  The physician should be familiar with the new advances in antileukemic therapy.</p>
<p><span class="Italics"><span class="Emphasis">Meningeal <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></span></span></p>
<p>In the treatment or prophylaxis of meningeal <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, methotrexate must be administered intrathecally.Â  Preservative free methotrexate is diluted to a concentration of 1 mg/mL in an appropriate sterile, preservative free medium such as 0.9% Sodium Chloride Injection, USP.</p>
<p>The cerebrospinal fluid volume is dependent on age and not on body surface area.Â  The CSF is at 40% of the adult volume at birth and reaches the adult volume in several years.</p>
<p>Intrathecal methotrexate administration at a dose of 12 mg/m<span class="Sup">2</span> (maximum 15 mg) has been reported to result in low CSF methotrexate concentrations and reduced efficacy in pediatric patients and high concentrations and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> in adults.Â  The following dosage regimen is based on age instead of body surface area:Â  </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Age (years)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Dose (mg)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â  &lt; 1</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â Â Â  6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â Â Â Â  1</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â  Â  8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â Â Â Â  2</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â Â  10</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3 or older</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â Â Â Â  12</p></td>
</tr>
</tbody></table>
<p>In one study in patients under the age of 40, this dosage regimen appeared to result in more consistent CSF methotrexate concentrations and less <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.Â  Another study in pediatric patients with <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span> compared this regimen to a dose of 12 mg/m<span class="Sup">2 </span>(maximum 15 mg), a significant reduction in the rate of CNS relapse was observed in the group whose dose was based on age. </p>
<p>Because the CSF volume and turnover may decrease with age, a dose reduction may be indicated in elderly patients. </p>
<p>For the treatment of meningeal <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, intrathecal methotrexate may be given at intervals of 2 to 5 days. Â However, administration at intervals of less than 1 week may result in increased subacute toxicity. Methotrexate is administered until the cell count of the cerebrospinal fluid returns to normal. Â At this point one additional dose is advisable.Â  For prophylaxis against meningeal <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, the dosage is the same as for treatment except for the intervals of administration. Â On this subject, it is advisable for the physician to consult the medical literature. </p>
<p>Untoward side effects may occur with any given intrathecal injection and are commonly neurological in character. Â Large doses may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.Â  Methotrexate given by the intrathecal route appears significantly in the systemic circulation and may cause systemic methotrexate toxicity. Â Therefore, systemic antileukemic therapy with the drug should be appropriately adjusted, reduced, or discontinued. Focal leukemic involvement of the central nervous system may not respond to intrathecal chemotherapy and is best treated with radiotherapy. </p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphomas</span></span></span></p>
<p>In Burkittâ€™s tumor, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. Â In Stage III, methotrexate is commonly given concomitantly with other antitumor agents. Â Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Â Lymphosarcomas in Stage III may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. </p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis Fungoides</span> (cutaneous T cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>)</span></span></p>
<p>Therapy with methotrexate as a single agent appears to produce clinical responses in up to 50% of patients treated. Â Dosage in early stages is usually 5 to 50 mg once weekly.Â  Dose reduction or cessation is guided by patient response and hematologic monitoring.Â  Methotrexate has also been administered twice weekly in doses ranging from 15 to 37.5 mg in patients who have responded poorly to weekly therapy. Â Combination chemotherapy regimens that include intravenous methotrexate administered at higher doses with leucovorin rescue have been utilized in advanced stages of the disease. </p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">Osteosarcoma</span></span></span></p>
<p>An effective adjuvant chemotherapy regimen requires the administration of several cytotoxic chemotherapeutic agents. Â In addition to high-dose methotrexate with leucovorin rescue, these agents may include doxorubicin, cisplatin, and the combination of bleomycin, cyclophosphamide and dactinomycin (BCD) in the doses and schedule shown in the table below. Â The starting dose for high-dose methotrexate treatment is 12 grams/m<span class="Sup">2</span>. Â If this dose is not sufficient to produce a peak serum methotrexate concentration of 1,000 micromolar (10<span class="Sup">-3</span> mol/L) at the end of the methotrexate infusion, the dose may be escalated to 15 grams/m<span class="Sup">2</span> in subsequent treatments. Â If the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or is unable to tolerate oral medication, leucovorin is given IV or IM at the same dose and schedule.Â Â  </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Drug<span class="Sup">*</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Dose<span class="Sup">*</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Treatment Week After Surgery</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Methotrexate</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">12 g/m<span class="Sup">2</span> IV as 4 hour infusion(starting dose)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4,5,6,7,11,12,15,16,29,30,44,45 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Leucovorin</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">15 mg orally every six hours for 10 doses starting at 24 hours after start of methotrexate infusion.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Â </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Doxorubicin<span class="Sup">â€ </span>Â </p>
<p>as a single drug</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">30 mg/m<span class="Sup">2</span>/day IV x 3 days</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">8,17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Doxorubicin<span class="Sup">â€ </span></p>
<p>Cisplatin<span class="Sup">â€ </span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">50 mg/m<span class="Sup">2</span> IV</p>
<p>100 mg/m<span class="Sup">2</span> IV</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">20,23,33,36</p>
<p>20,23,33,36</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Bleomycin<span class="Sup">â€ </span>Â </p>
<p>Cyclophosphamide<span class="Sup">â€ </span></p>
<p>Â Dactinomycin<span class="Sup">â€ </span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">15 units/m<span class="Sup">2</span> IV x 2 days </p>
<p>600 mg/m<span class="Sup">2</span> IV x 2 days </p>
<p>0.6 mg/m<span class="Sup">2</span> IV x 2 days</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">2,13,26,39,42</p>
<p>2,13,26,39,42</p>
<p>2,13,26,39,42</p>
</td>
</tr>
</tbody></table>
<p>Â <span class="Sup">*</span>Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span> of the extremity. <span class="Italics"><span class="Emphasis">N Engl J of Med</span></span> 1986; 314(No.25):1600-1606. </p>
<p><span class="Sup">â€ </span>See each respective package insert for full prescribing information. Â Dosage modifications may be necessary because of drug-induced toxicity.</p>
<p>Â When these higher doses of methotrexate are to be administered, the following safety guidelines should be closely observed. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c83eca75-819a-4667-9de2-9ae2d313be71"></a><a name="section-11"></a><p></p>
<h1>GUIDELINES FOR METHOTREXATE THERAPY WITH LEUCOVORIN RESCUE</h1>
<p class="First">1.Â  Administration of methotrexate should be delayed until recovery if:</p>
<ul>
<li>Â Â Â  the WBC count is less than 1,500/microliter </li>
<li>Â Â Â  the neutrophil count is less than 200/microliterÂ  </li>
<li>Â Â Â  the platelet count is less than 75,000/microliterÂ  </li>
<li>Â Â Â  the serum bilirubin level is greater than 1.2 mg/dL </li>
<li>Â Â Â  the SGPT level is greater than 450 U </li>
<li>Â Â Â  <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> is present, until there is evidence of healing </li>
<li>Â Â Â  persistent <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> is present; this should be drained dry prior to infusion.</li>
</ul>
<p>2.Â  Adequate renal function must be documented. Â Â Â </p>
<p>Â Â Â Â Â  a.Â Â  Serum creatinine must be normal, and creatinine clearance must be greater </p>
<p>Â Â Â Â Â Â Â Â Â Â Â  than 60 mL/min, before initiation of therapy. Â Â  </p>
<p>Â Â Â Â Â  b.Â Â  Serum creatinine must be measured prior to each subsequent course of therapy.Â  </p>
<p>Â Â Â Â Â Â Â Â Â Â Â  If serum creatinine has increased by 50% or more compared to a prior value, the creatinine </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â clearanceÂ must be measured and documented to be greater than 60 mL/min (even if the </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â serum creatinine is still within the normal range).Â  </p>
<p>3.Â Â  Patients must be well hydrated, and must be treated with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> for urinary </p>
<p>Â Â Â Â Â Â alkalinization. </p>
<p>Â Â Â Â Â  a.Â Â  Administer 1,000 mL/m<span class="Sup">2</span> of intravenous fluid over 6 hours prior to initiation of the methotrexate </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â infusion. Â Continue hydration at 125 mL/m<span class="Sup">2</span>/hr (3 liters/m<span class="Sup">2</span>/day) during the methotrexate </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â infusion,Â and for 2 days after theÂ infusion has been completed. </p>
<p>Â Â Â Â Â  b.Â Â  Alkalinize urine to maintain pH above 7.0 during methotrexate infusion and leucovorin calcium </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â therapy.Â This can beÂ accomplished by the administration of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> orally or by </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â incorporationÂ into a separate intravenous solution. </p>
<p>4.Â Â  Repeat serum creatinine and serum methotrexate 24 hours after starting methotrexate and at least once daily until the methotrexate level is below 5x10<span class="Sup">-8 </span>mol/L (0.05 micromolar). </p>
<p>5.Â Â  The table below provides guidelines for leucovorin calcium dosage based upon serum methotrexate levels.Â  (See table below.<span class="Sup">â€¡</span>)</p>
<p>Patients who experience delayed early methotrexate elimination are likely to develop non-reversible oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.Â  In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has resolved.Â  If necessary, acute, intermittent hemodialysis with a high-flux dialyzer may also be beneficial in these patients.</p>
<p>6.Â Â  Some patients will have abnormalities in methotrexate elimination, or abnormalities in renal function following methotrexate administration, which are significant but less severe than the abnormalities described in the table below.Â  These abnormalities may or may not be associated with significant clinical toxicity.Â  If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total 14 doses over 84 hours) in subsequent courses of therapy.Â  The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate binding to serum albumin, or elimination) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.</p>
<p>CAUTION: DO NOT ADMINISTER LEUCOVORIN INTRATHECALLY. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="de44088c-9c3e-4313-94fe-11e84efb7962"></a><a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span>, and <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">Juvenile Rheumatoid Arthritis</span></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Adult <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></span></span></p>
<p><span class="Italics"><span class="Emphasis">Recommended Starting Dosage Schedules</span></span></p>
<p>1. Single oral doses of 7.5 mg once weekly.<span class="Sup"> â€ </span></p>
<p>2. Divided oral dosages of 2.5 mg at 12 hour intervals for 3 doses given as a course once weekly.<span class="Sup"> â€  </span></p>
<p><span class="Sup">Â Â Â Â  â€ </span>Methotrexate Sodium Tablets for oral administration are available. </p>
<p><span class="Bold"><span class="Emphasis">Polyarticular-Course <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">Juvenile Rheumatoid Arthritis</span></span></span></p>
<p>The recommended starting dose is 10 mg/m<span class="Sup">2</span> given once weekly. </p>
<p>For either adult RA or polyarticular-course JRA dosages may be adjusted gradually to achieve an optimal response.Â  Limited experience shows a significant increase in the incidence and severity of serious toxic reactions, especially bone marrow suppression, at doses greater than 20 mg/wk in adults. Â Although there is experience with doses up to 30 mg/m<span class="Sup">2</span>/wk in children, there are too few published data to assess how doses over 20 mg/m<span class="Sup">2</span>/wk might affect the risk of serious toxicity in children. Â Experience does suggest, however, that children receiving 20 to 30 mg/m<span class="Sup">2</span>/wk (0.65 to 1 mg/kg/wk) may have better absorption and fewer gastrointestinal side effects if methotrexate is administered either intramuscularly or subcutaneously.</p>
<p>Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more. </p>
<p>The optimal duration of therapy is unknown. Â Limited data available from long-term studies in adults indicate that the initial clinical improvement is maintained for at least two years with continued therapy. Â When methotrexate is discontinued, the <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> usually worsens within 3 to 6 weeks. </p>
<p><span class="Italics"><span class="Emphasis">The patient should be fully informed of the risks involved and should be under constant supervision of the physician</span></span> (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#c97c9e33-380a-4144-8b10-ac48208d54f5">Information for Patients</a>Â </span></span></span>under <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>).Â  Assessment of hematologic, hepatic, renal, and pulmonary function should be made by history, physical examination, and laboratory tests before beginning, periodically during, and before reinstituting methotrexate therapy (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a></span></span>).Â  Appropriate steps should be taken to avoid conception during methotrexate therapy (see <span class="Bold"><span class="Emphasis"><a href="#a38ec796-9705-4763-8802-3a88cd2e26c8">PRECAUTIONS</a>Â </span></span>and <span class="Bold"><span class="Emphasis"><a href="#a15d5648-439e-4a6d-b23d-1c02c0329aff">CONTRAINDICATIONS</a></span></span>). </p>
<p>All schedules should be continually tailored to the individual patient. Â An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects (see <span class="Bold"><span class="Emphasis"><a href="#a9b7e966-af5e-44a9-bb63-a00d00547551">ADVERSE REACTIONS</a></span></span>). Â Maximal <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> usually occurs in seven to ten days. </p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></span></span></p>
<p><span class="Italics"><span class="Emphasis">Recommended Starting Dose Schedules</span></span></p>
<p>1.Â  Weekly single oral, IM or IV dose schedule: 10 to 25 mg per week until adequate response is achieved.<span class="Sup"> â€ </span></p>
<p>2.Â  Divided oral dose schedule: 2.5 mg at 12 hour intervals for three doses.<span class="Sup"> â€  </span></p>
<p><span class="Sup">Â Â Â Â Â Â  â€ </span>Methotrexate Sodium Tablets for oral administration are available. </p>
<p>Dosages in each schedule may be gradually adjusted to achieve optimal clinical response; 30 mg/week should not ordinarily be exceeded. </p>
<p>Once optimal clinical response has been achieved, each dosage schedule should be reduced to the lowest possible amount of drug and to the longest possible rest period.Â  The use of methotrexate may permit the return to conventional topical therapy, which should be encouraged.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="cbdd540d-b5d9-4b05-82f9-2f3adc6173f6"></a><a name="section-12"></a><p></p>
<h1>HANDLING AND DISPOSAL</h1>
<p class="First">Procedures for proper handling and disposal of anticancer drugs should be considered.Â  Several guidelines on this subject have been published.<span class="Sup">1-7 </span>There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b2a4dd2a-3205-4569-b738-f795448557a9"></a><a name="section-13"></a><p></p>
<h1>RECONSTITUTION OF LYOPHILIZED POWDERS</h1>
<p class="First">Reconstitute immediately prior to use.</p>
<p>Methotrexate for Injection, USP, should be reconstituted with an appropriate sterile, preservative free medium such as 5% Dextrose Solution, USP, or Sodium Chloride Injection, USP.Â  <span class="Bold"><span class="Emphasis">The 1 gram vial should be reconstituted with 19.4 mL to a concentration of 50 mg/mL</span></span>.Â  When high doses of methotrexate are administered by IV infusion, the total dose is diluted in 5% Dextrose Solution.</p>
<p>For intrathecal injection, reconstitute to a concentration of 1 mg/mL with an appropriate sterile, preservative free medium such as Sodium Chloride Injection, USP.</p>
<p>Â <span class="Bold"><span class="Emphasis"><span class="Sup">â€¡</span></span></span><span class="Bold"><span class="Emphasis">LEUCOVORIN RESCUE SCHEDULES FOLLOWING TREATMENT WITH HIGHER DOSES OF METHOTREXATE</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Clinical Situation </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Laboratory Findings </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Leucovorin Dosage and Duration </span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Normal Methotrexate Elimination </p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Serum methotrexate level approximately 10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">15 mg PO, IM, or IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Delayed Late Methotrexate Elimination </p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Serum methotrexate level remaining above 0.2 micromolar at 72 hours, and more than 0.05 micromolar at 96 hours after administration. </p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Continue 15 mg PO, IM, or IV q 6 hours, until methotrexate level is less than 0.05 micromolar. </p>
<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Delayed Early Methotrexate Elimination and/or Evidence of Acute <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">Renal Injury</span> </p>
<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Serum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase from 0.5 mg/dL to a level of 1 mg/dL or more).</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">150 mg IV q 3 hours, until methotrexate level is less than 1 micromolar; then 15 mg IV q 3 hours, until methotrexate level is less than 0.05 micromolar.</p></td>
</tr>
</tbody></table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f06543aa-2ded-4eb7-9219-4db111d3d795"></a><a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="c2add28e-9559-4bf0-97b5-8d735e409803"></a><a name="section-14.1"></a><p></p>
<h2>Parenteral</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Methotrexate for Injection, USP, Lyophilized, Preservative Free, for Single Use Only</span></span>.Â  </p>
<p>Each 1 g vial of lyophilized powder contains methotrexate sodium equivalent to 1 g methotrexate. </p>
<p><span class="Bold"><span class="Emphasis">ProductÂ Â Â Â Â  Â Â Â Â Â  NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No. Â Â Â Â Â  Â Â Â Â Â  Â Â Â Â Â Â  No.</span></span></p>
<p>NP102250Â Â Â Â Â Â Â Â 63323-122-59Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  1 gÂ  per vial</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].Â  PROTECT FROM LIGHT.Â  Retain in carton until time of use.Â  Discard unused portion.Â  </p>
<p>This container closure is not made with natural rubber latex.</p>
<p><span class="Bold"><span class="Emphasis">See package insert for routes of administration.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ad7c7c8b-ac74-4298-9dd2-79f1ecc60ca9"></a><a name="section-15"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Controlling Occupational Exposure to Hazardous Drugs (OSHA Work-Practice Guidelines).<span class="Italics"><span class="Emphasis"> Am J Health Syst Pharm </span></span>1996; 53:1669-1685.</li>
<li>Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.</li>
<li>AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. <span class="Italics"><span class="Emphasis">JAMA</span></span>, 1985; 253(11): 1590-1592.</li>
<li>National Study Commission on Cytotoxic Exposure â€“ Recommendations for  Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of  Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.</li>
<li>Clinical Oncological Society of Australia: Guidelines and Recommendations for Safe Handling of Antineoplastic Agents.<span class="Italics"><span class="Emphasis"> Med J Australia </span></span>1983; 1:426-428.</li>
<li>Jones RB, et al. Safe Handling of Chemotherapeutic Agents: A Report From the Mount Sinai Medical Center. Ca â€“<span class="Italics"><span class="Emphasis"> A Cancer Journal for Clinicians</span></span> Sept/Oct 1983; 258-263.</li>
<li>American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs.<span class="Italics"><span class="Emphasis"> Am J Hosp Pharm </span></span>1990; 47:1033-1049.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d4989ef4-5084-49d6-99aa-55bdf1fdb67e"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First">N+ and Novaplus are registered trademarks of Novation, LLC.</p>
<p>Manufactured by:</p>
<p><span class="Bold"><span class="Emphasis">Fresenius Kabi USA, LLC</span></span></p>
<p>Lake Zurich, IL 60047</p>
<p>451361</p>
<p>Issued: November 2013</p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&amp;name=methotrexate-for-injection-usp-figure-2-nplogo.jpg"></p>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="b462497e-5750-4296-bae1-1cab318305cc"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL- PRINCIPAL DISPLAY- Methotrexate for Injection 1 g Vial Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-122-59</p>
<p>NP102250</p>
<p><span class="Bold"><span class="Emphasis">Methotrexate for Injection, USP</span></span></p>
<p>Cytotoxic Agent</p>
<p><span class="Bold"><span class="Emphasis">1 g per vial</span></span></p>
<p>Rx only</p>
<p>Lyophilized</p>
<p>Preservative Free</p>
<p>Single Dose Vial </p>
<p><img alt="np102250" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&amp;name=methotrexate-for-injection-usp-figure-3-np102250-vial.jpg"></p>
<br><p><span class="Bold"><span class="Emphasis">PACKAGE LABEL- PRINCIPAL DISPLAY- Methotrexate for Injection 1 g Vial Carton Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-122-59</p>
<p>NP102250</p>
<p><span class="Bold"><span class="Emphasis">Methotrexate for Injection, USP</span></span></p>
<p>Cytotoxic Agent</p>
<p><span class="Bold"><span class="Emphasis">1 g per vial</span></span></p>
<p>Rx only</p>
<p>Lyophilized</p>
<p>Preservative Free</p>
<p>See package insert for routes of administration.</p>
<p>Single Dose Vial</p>
<p><img alt="np102250" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&amp;name=methotrexate-for-injection-usp-figure-4-np102250-pbox.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHOTREXATEÂ 		
					</strong><br><span class="contentTableReg">methotrexate sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-122</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, INTRA-ARTERIAL, INTRATHECAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHOTREXATE SODIUM</strong> (METHOTREXATE) </td>
<td class="formItem">METHOTREXATE</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-122-59</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040266</td>
<td class="formItem">01/22/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE(63323-122)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5c7e2919-468d-457f-bbf9-e31c89070a81</div>
<div>Set id: 6cf2e15a-6286-41f7-aa7d-3968d735c864</div>
<div>Version: 1</div>
<div>Effective Time: 20140515</div>
</div>
</div>Â <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
